Theravance Biopharma, Inc. · NASDAQ:TBPH

Theravance Biopharma — Technical Presentation (November 2014)

10 slides from Theravance Biopharma's technical presentation, Nov 3, 2014

  1. Slide 1: TD-6450 Phase 1 Study 0110 Results for Cohorts 1-3

    Medicines that make a difference © 2014 Theravanc e Biopharma. All rights reserved. THERAVANCE®, the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of the Theravance Biopharma group of companies. TD-6450 Phase 1 Study 0110 Results for Cohorts 1-3 November 3, 2014 Exh

  2. Slide 2: Safe Harbor Statement

    2 Safe Harbor Statement This presentation contains certain " forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives and future events. Theravance Biopharma intends such

  3. Slide 3: HCV Discovery Program: Multivalent Approach to Discover NS5A Inhibitors

    3 HCV Discovery Program at Theravance Biopharma: Multivalent Approach to Discover NS5A Inhibitors NS5A inhibitors have emerged as a preferred component of all-oral HCV therapy Next-generation NS5A inhibitors have the potential to shorten HCV treatment duration and increase SVR rates in harder-to-tre

  4. Slide 4: Positive Results in Proof-of-Concept Study in GT-1a HCV Patients

    4 Positive Results in TD-6450 Phase 1 Proof-of-Concept Study in GT-1a HCV Patients GT: genotype LOD = limit of detection Median maximal decline of HCV RNA of 4.9 lig10 IU/mL at 240 mg 4/7 patients at 240 mg achieved levels of serum HCV RNA below LOD 100% of patients achieved at leaset 3 log10 reduct

  5. Slide 5: Proof-of-Concept Study Design

    5 TD-6450 Phase 1 Proof-of-Concept Study Design GT: genotype

  6. Slide 6: TD-6450 Demonstrated Dose-Dependent Antiviral Activity in GT-1a HCV Patients

    6 TD-6450 Demonstrated Dose-Dependent Antiviral Activity in GT-1a HCV Patients Subjects with maximum decline less than limit of detection (LOD) imputed as LOD/2 on log10 scale 60 120 240 Median Maximum Decline HCV RNA(log10 IU/mL) -6 -5 -4 -3 -2 -1 0 1 -3.87 -4.63 -4.89 TD-6450 (mg) GT: genotype

  7. Slide 7: TD-6450 Demonstrated Dose-Dependent Antiviral Activity

    7 TD-6450 Demonstrated Dose-Dependent Antiviral Activity: 100% of GT-1a patients achieved at least 3 log10 reduction in HCV RNA Reduction in HCV RNA (log10 IU/mL) R epo rted as n( %) TD-6450 60 mg (N=7) TD-6450 120 mg (N=7) TD-6450 240 mg (N=7) = 3.0 7 (100) 7 (100) 7 (100) = 3.5 7 (100) 6 (86) 6 (8

  8. Slide 8: Rapid and Sustained Reduction in HCV RNA in GT-1a Patients

    8 Rapid and Sustained Reduction in HCV RNA at 240 mg Dose in GT-1a Patients Reduction in Virus Maintained from 8-28 Days after First Dose Last Dose GT: genotype

  9. Slide 9: Adverse Event Profile: Generally Well-Tolerated

    9 Adverse Event Profile: Generally Well-Tolerated Cohorts 1-3 Placebo (N=3) TD-6450 60 mg (N=7) TD-6450 120 mg (N=7) TD-6450 240 mg (N=7) Subjects with any adverse event (AE) 1 (33.3%) 4 (57.1%) 1 (14.3%) 1 (14.3%) All AEs Upper abdominal pain 1 (14.3%) Nausea 1 (14.3%) Chest pain 1 (14.3%) Catheter

  10. Slide 10: Proof-of-Concept Results Summary in GT-1a HCV Patients

    10 TD-6450 Phase 1 Proof-of-Concept Results Summary in GT-1a HCV Patients Rapid and sustained antiviral activity after 3 days of dosing Median maximal declines of HCV RNA of 4.9 log10 IU/mL at 240 mg Generally well-tolerated Data gathering and analysis for cohorts 4 - 7 ongoing GT: genotype Data Sug

Theravance Biopharma — Technical Presentation (November 2014) on 6ix